AELMHU calls for orphan and ultra-orphan drugs to be excluded from the sixth additional provision
AELMHU is calling for orphan drugs to be exempt from the new financial obligation set forth in the upcoming Medicines Act. The Spanish Association of Orphan and Ultra-Orphan Drug Manufacturers (AELMHU) has asked the government ... Read more
July 7, 2026
The rare disease pharmaceutical sector generates nearly 7,000 jobs in Spain and is expected to continue growing through 2026
The pharmaceutical sector specializing in rare diseases continues to grow in Spain and already accounts for nearly 7,000 jobs, including both direct and indirect positions. In addition, companies plan to continue expanding their workforces throughout 2026 after ... Read more
July 2, 2026
Joint Statement by Spanish Associations in the Pharmaceutical and Cosmetics Sectors Regarding the European Directive on Urban Wastewater Treatment
The Spanish associations in the pharmaceutical and cosmetics sectors—AELMHU, Aeseg, Anefp, AseBio, BioSim, Farmaindustria, and Stanpa—wish to express our firm commitment to sustainability, environmental protection, and improvement ... Read more
June 18, 2026
The media: Key partners in raising awareness of rare diseases
The National Association of Health Reporters (ANIS) and the Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (AELMHU) organized a new edition of the Training Workshop for Journalists this Thursday ... Read more
June 17, 2026
First Quarterly Access Report 2026
The Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (AELMHU) has published its Report on Access to Orphan Drugs in Spain for the first four months of 2026, with data through April 30. This publication, ... Read more
June 4, 2026
AELMHU Participates in the Third Edition of Únicas Talks
Beatriz Perales, president of the Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (AELMHU), participated this Thursday in the third edition of Únicas Talks, a conference organized by Sant Joan Hospital ... Read more
